Redmile Group, LLC 13D and 13G filings for ADC Therapeutics S.A.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 4:15 pm Sale | 2025-06-30 | 13G | ADC Therapeutics S.A. ADCT | Redmile Group, LLC | 15,666,731 14.000% | -2,486 (-0.02%) | Filing |
| 2024-11-14 9:00 pm Purchase | 2024-09-30 | 13G | ADC Therapeutics S.A. ADCT | Redmile Group, LLC | 15,669,217 16.200% | 340,900 (+2.22%) | Filing |
| 2024-02-14 4:26 pm Purchase | 2023-12-31 | 13G | ADC Therapeutics S.A. ADCT | Redmile Group, LLC | 15,328,317 18.800% | 1,763,068 (+13.00%) | Filing |
| 2023-02-10 5:18 pm Purchase | 2022-12-31 | 13G | ADC Therapeutics S.A. ADCT | Redmile Group, LLC | 13,565,249 16.800% | 6,114,220 (+82.06%) | Filing |
| 2022-02-14 5:07 pm Purchase | 2021-12-31 | 13G | ADC Therapeutics S.A. ADCT | Redmile Group, LLC | 7,451,029 9.700% | 692,235 (+10.24%) | Filing |
| 2021-02-16 4:05 pm Purchase | 2020-12-31 | 13G | ADC Therapeutics S.A. ADCT | Redmile Group, LLC | 6,758,794 8.810% | 6,758,794 (New Position) | Filing |